Mar 2018

NATIONAL EVIDENCE REVIEW RELEASED

The Commonwealth Department of Health, in conjunction with state and territory governments, has helped coordinate the development of new clinical guidance documents for medicinal cannabis products. It includes a national review of the scientific evidence for the use of cannabis medicines in five areas: palliative care, nausea and vomiting, epilepsy, multiple sclerosis and pain.

More information is available on the TGA website and can be found here.

We’re thrilled to announce we have received our export licence from the Drug Control Section of the ODC (Office of Drug Control). We’re firmly on course to continue to lead the way and be the first medicinal cannabis company in Australia to export cannabis flower to the EU since export was legalised in 2018.

READ MORE >

We have successfully passed three consecutive TGO93 and TGO100 tests on our medicinal cannabis products since our first commercial harvest at the end of 2019.

READ MORE >

One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.

READ MORE >

We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.

LEARN ABOUT ANTG HERE >